You are here

Article Text

Article menu

Download PDFPDF

Invited Speaker Presentation
S82. Proffered paper: In-vivo testing of PSMA-targeted T-cell immunotherapy for prostate cancer
  1. Z Liu1,
  2. SB Papa1,
  3. J Morris1 and
  4. J Maher1
  1. Aff1 grid.13097.3c0000 0001 2322 6764Kings College London and Guys and St Thomas' NHS Foundation TrustCancer Studies London UK

https://doi.org/10.1186/2051-1426-2-S2-I20

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Introduction

    Bone is the most common site for metastasis in human prostate cancer patients. Skeletal metastases are a significant cause of morbidity and mortality and overall greatly affect the quality of life of prostate cancer patients. Despite advances in our understanding of the biology of primary prostate tumours, our knowledge of how and why secondary tumours derived from prostate cancer cells preferentially localise in bone remains limited. Examining the impact of these facets of bone metastasis in vivo remains a significant challenge, as animal models that closely mimic the natural history and malignant progression of clinical prostate cancer are not available.

    Objectives

    To develop an animal model of human metastatic prostate cancer. Once a model has been developed and optimised, it was this to test efficacy of immunotherapy using T-cells that have been genetically targeted against prostate-specific membrane antigen (PSMA).

    Material and methods

    Using PCR, western blot, flow cytometry and ELISA, we performed functional anaylsis of fucosyltransferase 3(FT3) in PC3LN3(PL)and PC3LN3-PSMA (PLP) tumour cell lines. In vivo bioluminescent imaging (BLI) was used to detect metastases.

    Results

    In preliminary studies, we have observed that delivery of a FT3-encoding retroviral vector to PL and PLP enables them to express sialyl Lewis X and to acquire E-selectin binding activity. We also showed that FT3 promotes increased PLP motility and invasiveness in vitro. Bioluminescent animal model of metastasised prostate cancer is established to determine the effect of this upon their pattern of metastatic spread in SCID Beige mice.

    Conclusion

    We have established an in-vivo model of PSMA-expressing prostate cancer. This will serve as a platform to test immunotherapy using P28z+ T-cells.